{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T03:13:14Z","timestamp":1778209994190,"version":"3.51.4"},"reference-count":42,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2020,5,27]]},"abstract":"<jats:sec><jats:title\/><jats:p>This review refers to the all-inclusive details of Lorcaserin Hydrochloride on comprehensive information about the synthesis, analytical methods, pharmacodynamics, pharmacokinetics, drug interactions and adverse effects. Lorcaserin Hydrochloride is chemically (R)-8-Chloro-1-methyl-2,3,4,5- tetrahydro-1H-3-benzazepine hydrochloride. Lorcaserin HCl is a novel, synthetic, centrally-acting selective serotonin C (5-HT2c) receptor, l agonist, which results in increased satiety and decreased food consumption in patients. Headache, dizziness and nausea are the most common side effects associated with this drug. Lorcaserin HCl has two major metabolites, one conjugated with glucuronide called N-carbamoyl glucuronide which is excreted in urine and the second Lorcaserin N-sulfamate, which is circulated in the blood. Lorcaserin HCl is synthesized using four different schemes of which a six-step method that resulted in 92.3% yield with 99.8% of purity is employed for scale-up production. It is analyzed quantitatively in the plasma and brain tissue matrix of rats by Ultra Performance Liquid chromatographic (UPLC) method using MS-MS (Mass Spectrometric) detection.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389557519666190408154443","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T10:30:04Z","timestamp":1554805804000},"page":"768-778","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Chemistry, Analysis, Pharmacokinetics and Pharmacodynamics Aspects of Lorcaserin, a Selective Serotonin 5-HT2C Receptor Agonist: An Update"],"prefix":"10.2174","volume":"20","author":[{"given":"Sanjay","family":"Sharma","sequence":"first","affiliation":[{"name":"Quality Assurance, School of Pharmacy and Technology Management, NMIMS, Shirpur, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Komal S.","family":"Aware","sequence":"additional","affiliation":[{"name":"Quality Assurance, School of Pharmacy and Technology Management, NMIMS, Shirpur, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ketan","family":"Hatware","sequence":"additional","affiliation":[{"name":"Pharmacology, School of Pharmacy and Technology Management, NMIMS, Shirpur, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiran","family":"Patil","sequence":"additional","affiliation":[{"name":"Pharmaceutics, School of Pharmacy and Technology Management, NMIMS, Shirpur, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1021\/jf5007352","volume":"62","author":"Asyifah M.R.","year":"2014","unstructured":"Asyifah M.R.; Lu K.; Ting H.L.; Zhang D.; Hidden potential of tropical fruit waste components as a useful source of remedy for obesity. J Agric Food Chem 2014,62(16),3505-3516","journal-title":"J Agric Food Chem"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.clinthera.2016.08.016","volume":"38","author":"Christopher R.","year":"2016","unstructured":"Christopher R.; Morgan M.; Ferry J.; Rege B.; Tang Y.; Kristensen A.; Shanahan W.; Single and multiple-dose pharmacokinetics of a lorcaserin extended-release tablet. Clin Ther 2016,38(10),2227-2238","journal-title":"Clin Ther"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4093\/dmj.2012.36.1.13","volume":"36","author":"Kang J.G.","year":"2012","unstructured":"Kang J.G.; Park C.; Anti-Obesity drugs: A review about their effects and safety. Diabetes Metab J 2012,36(1),13-25","journal-title":"Diabetes Metab J"},{"key":"ref=4","first-page":"2015","author":"Dixon J.B.","year":"2016","unstructured":"Dixon J.B.; Advances in managing obesity. Nat Publ Gr, 2016,2015-2016","journal-title":"Nat Publ Gr,"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/2040622314522848","volume":"5","author":"Manning S.","year":"2014","unstructured":"Manning S.; Pucci A.; Finer N.; Pharmacotherapy for obesity: Novel agents and paradigms. Ther Adv Chronic Dis 2014,5(3),135-148","journal-title":"Ther Adv Chronic Dis"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/oby.21136","volume":"23","author":"Xia Y.","year":"2015","unstructured":"Xia Y.; Kelton C.M.L.; Guo J.J.; Bian B.; Heaton P.C.; Treatment of obesity: Pharmacotherapy trends in the united states from 1999 to 2010. Obesity 2015,23,1721-1728","journal-title":"Obesity"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1177\/193229680800200525","volume":"2","author":"Klonoff D.C.","year":"2008","unstructured":"Klonoff D.C.; Greenway F.; Drugs in the pipeline for the obesity market. J Diabetes Sci Technol 2008,2,913-918","journal-title":"J Diabetes Sci Technol"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2147\/DMSO.S95299","volume":"10","author":"Hendricks E.J.","year":"2017","unstructured":"Hendricks E.J.; Off-Label drugs for weight management. Diabetes Metabol. Syndrome Obesity: Targets Therapy 2017,10,223-234","journal-title":"Syndrome Obesity: Targets Therapy"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3810\/pgm.2014.10.2817","volume":"126","author":"Aronne L.","year":"2014","unstructured":"Aronne L.; Shanahan W.; Fain R.; Glicklich A.; Soliman W.; Smith S.; Safety and efficacy of lorcaserin: A combined analysis of the BLOOM and BLOSSOM trials. Postgrad Med 2014,126,7-18","journal-title":"Postgrad Med"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"506","DOI":"10.2174\/092986709787315568","volume":"16","author":"Gurevich-panigrahi T.","year":"2009","unstructured":"Gurevich-panigrahi T.; Panigrahi S.; Wiechec E.; Los M.; Obesity: Pathophysiology and clinical management. Curr Med Chem 2009,16(4),506-521","journal-title":"Curr Med Chem"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.tins.2012.12.001","volume":"36","author":"Adan R.A.H.","year":"2013","unstructured":"Adan R.A.H.; Mechanisms Underlying current and future anti-obesity drugs. Trends Neurosci 2013,36,133-140","journal-title":"Trends Neurosci"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pop.2015.08.011","volume":"43","author":"Rodr\u00edguez J.E.","year":"2016","unstructured":"Rodr\u00edguez J.E.; Past, present and future pharmacological therapy in obesity stimulants fat blockers antidepressants pharmacology treatment. Prim Care Mar, 2016,43(1),61-67","journal-title":"Prim Care Mar,"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1575-0922(09)73516-8","volume":"56","author":"Lois K.","year":"2009","unstructured":"Lois K.; Kumar S.; Pharmacotherapy of Obesity. Endocrinol Nutr 2009,56(4),223-235","journal-title":"Endocrinol Nutr"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1242\/dmm.009621","volume":"5","author":"Rodgers R.J.","year":"2012","unstructured":"Rodgers R.J.; Tschop M.H.; Wilding J.P.H.; Anti-Obesity drugs: Past, present and future. Dis Model Mech 2012,5,621-626","journal-title":"Dis Model Mech"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11892-002-0105-3","volume":"2","author":"Hatahet M.A.","year":"2002","unstructured":"Hatahet M.A.; Dhurandhar N.V.; Antiobesity drugs: Current and future issues. Curr Diab Rep 2002,2,409-415","journal-title":"Curr Diab Rep"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.yrtph.2007.03.006","volume":"48","author":"Colman E.","year":"2007","unstructured":"Colman E.; Dinitrophenol and obesity: An early twentieth-century regulatory dilemma. Regul Toxicol Pharmacol 2007,48,115-117","journal-title":"Regul Toxicol Pharmacol"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/ijcp.12771","volume":"70","author":"Haslam D.","year":"2016","unstructured":"Haslam D.; Weight Management In Obesity \u2013 Past and present. Int J Clin Pract 2016,70(3),206-217","journal-title":"Int J Clin Pract"},{"key":"ref=18","doi-asserted-by":"crossref","DOI":"10.1201\/9780203508756","volume":"Vol. 5","author":"Hofbauer E.","year":"2004","unstructured":"Hofbauer E.; Karl G.; Data O.B.; Pharmacotherapy of Obesity 2004,Vol. 5","journal-title":"Pharmacotherapy of Obesity"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1021\/cn100059u","volume":"17","author":"Hopkins C.R.","year":"2010","unstructured":"Hopkins C.R.; ACS chemical neuroscience molecule spotlight on lorcaserin. ACS Chem Neurosci 2010,17(11),718-719","journal-title":"ACS Chem Neurosci"},{"key":"ref=20","first-page":"363","author":"Smith S.R.","year":"2010","unstructured":"Smith S.R.; Weissman N.J.; Anderson C.M.; Sanchez M.; Chuang E.; Stubbe S.; Bays H.; Shanahan W.R.; Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010,363","journal-title":"N Engl J Med"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.drudis.2009.02.008","volume":"14","author":"Zhao H.","year":"2009","unstructured":"Zhao H.; Guo Z.; Medicinal chemistry strategies in follow-on drug discovery. Drug Discov Today 2009,14,516-522","journal-title":"Drug Discov Today"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1358\/dot.2010.46.12.1556433","volume":"46","author":"Redman L.M.","year":"2010","unstructured":"Redman L.M.; Ravussin E.; Lorcaserin for the treatment of obesity. Drugs Today 2010,46,901-910","journal-title":"Drugs Today"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40265-013-0035-1","volume":"73","author":"Hoy S.M.","year":"2013","unstructured":"Hoy S.M.; Lorcaserin: A review of its use in chronic weight management. Drugs 2013,73,463-473","journal-title":"Drugs"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","volume":"363","author":"Smith S.R.","year":"2010","unstructured":"Smith S.R.; Weissman N.J.; Anderson C.M.; Sanchez M.; Chuang E.; Stubbe S.; Bays H.; Shanahan W.R.; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) study group.Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010,363,245-256","journal-title":"N Engl J Med"},{"key":"ref=25","first-page":"26","author":"Harmonization R.","year":"2012","unstructured":"Harmonization R.; Programme M.; Issues E.; WHO Drug Information 2012,26","journal-title":"WHO Drug Information"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1021\/acs.oprd.5b00144","volume":"19","year":"2015","unstructured":"Qihua Zhu; Wang, J.; Bian, X.; Zhang, L.; Wei, P.; Xu, Y. Novel synthesis of anti-obesity drug lorcaserin hydrochloride. Org Process Res Dev 2015,19,1263-1267","journal-title":"Org Process Res Dev"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.bmc.2017.12.009","volume":"26","author":"Cluzeau J.","year":"2018","unstructured":"Cluzeau J.; Stavber G.; Development and optimization of a new synthetic process for lorcaserin. Bioorg Med Chem 2018,26,977-983","journal-title":"Bioorg Med Chem"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1124\/jpet.107.133348","volume":"325","author":"Thomsen W.J.","year":"2008","unstructured":"Thomsen W.J.; Grottick A.J.; Menzaghi F.; Reyes-saldana H.; Espitia S.; Yuskin D.; Whelan K.; Martin M.; Morgan M.; Chen W.; Al-shamma H.; Smith B.; Chalmers D.; Behan D.; Lorcaserin, a novel selective human 5-hydroxytryptamine 2c agonist: In Vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 2008,325,577-587","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/jat\/bkv126","volume":"40","author":"Bajrai A.A.","year":"2016","unstructured":"Bajrai A.A.; Ezzeldin E.; Al-rashood K.A.; Raish M.; Iqbal M.; Article A validated UPLC \u2013 MS-MS assay for the rapid determination of lorcaserin in plasma and brain tissue samples. J Anal Toxicol 2016,40(2),133-139","journal-title":"J Anal Toxicol"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/chir.22793","volume":"30","author":"Wani D.V.","year":"2018","unstructured":"Wani D.V.; Rane V.P.; Mokale S.N.; Liquid chromatographic separation and thermodynamic investigation of lorcaserin hydrochloride enantiomers on immobilized amylose-based chiral stationary phase. Chirality 2018,30,284-292","journal-title":"Chirality"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4172\/pharmaceutical-sciences.1000350","volume":"80","author":"Rajput S.J.","year":"2018","unstructured":"Rajput S.J.; Sathe M.A.; Patel S.D.; Development and validation of a hplc-based bioanalytical method for lorcaserin using solid phase extraction and application to a pharmacokinetic study in rats. Indian J Pharm Sci 2018,80,235-241","journal-title":"Indian J Pharm Sci"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jpba.2014.05.003","volume":"98","author":"Hachem R.","year":"2014","unstructured":"Hachem R.; Malet-Martino M.; Gilard V.; First identification and quantification of lorcaserin in an herbal slimming dietary supplement. J Pharm Biomed Anal 2014,98,94-99","journal-title":"J Pharm Biomed Anal"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1586\/erc.10.22","volume":"9","author":"Bays H.E.","year":"2011","unstructured":"Bays H.E.; Lorcaserin: Drug profile and illustrative model of the regulatory challenges of weight-loss drug development. Expert Rev Cardiovasc Ther 2011,9,265-277","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"ref=34","year":"2012","unstructured":"Fda Briefing Document Nda 200677 Pasireotide Injection: 600 Mcg, 900 Mcg Sponsor: Novartis Pharmaceuticals Endocrinologic and Metabolic Drugs Advisory Committee Meeting. 2012"},{"key":"ref=35","first-page":"1","author":"Colman E.","year":"2010","unstructured":"Colman E.; Department of health and human services public, health service food and drug administration center for drug evaluation and research 2010,1-11","journal-title":"Department of health and human services public, health service food and drug administration center for drug evaluation and research"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/oby.21811","volume":"25","author":"Smith S.R.","year":"2017","unstructured":"Smith S.R.; Garvey W.T.; Greenway F.L.; Zhou S.; Fain R.; Pilson R.; Fujioka K.; Aronne L.J.; Coadministration of lorcaserin and phentermine for weight management: A 12-Week, randomized, pilot safety study. Obesity (Silver Spring) 2017,25,857-865","journal-title":"Obesity (Silver Spring)"},{"key":"ref=37","author":"For A.","year":"2012","unstructured":"For A.; Disclosure P.; Redaction W.; Lorcaserin hydrochloride briefing document for FDA advisory committee meeting 2012","journal-title":"Lorcaserin hydrochloride briefing document for FDA advisory committee meeting"},{"key":"ref=38","author":"Hurren K.M.","year":"2011","unstructured":"Hurren K.M.; Berlie H.D.; Lorcaserin: An Investigational Serotonin 2C Agonist for Weight Loss. Am J Heal Pharm, 68, 2029 LP-2037.2011","journal-title":"Am J Heal Pharm,"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1517\/14656566.2015.1096345","volume":"16","author":"Shukla A.P.","year":"2015","unstructured":"Shukla A.P.; Kumar R.B.; Aronne L.J.; Lorcaserin Hcl for the Treatment of Obesity. Expert Opin Pharmacother 2015,16,2531-2538","journal-title":"Expert Opin Pharmacother"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1124\/dmd.111.043448","volume":"40","author":"Sadeque A.J.M.","year":"2012","unstructured":"Sadeque A.J.M.; Usmani K.A.; Palamar S.; Cerny M.A.; Chen W.G.; Identification of Human UDP-Glucuronosyltransferases Involved in N-Carbamoyl Glucuronidation of Lorcaserin. Drug Metab Dispos 2012,40,772-778","journal-title":"Drug Metab Dispos"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1124\/dmd.115.067397","volume":"44","author":"Sadeque A.J.M.","year":"2016","unstructured":"Sadeque A.J.M.; Palamar S.; Usmani K.A.; Chen C.; Cerny M.A.; Chen W.G.; Identification of Human Sulfotransferases Involved in Lorcaserin N-Sulfamate Formation. Drug Metab Dispos 2016,44,570-575","journal-title":"Drug Metab Dispos"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1517\/17425255.2013.798643","volume":"9","author":"Berlie H.D.","year":"2013","unstructured":"Berlie H.D.; Hurren K.M.; Evaluation of Lorcaserin for the Treatment of Obesity. Expert Opin Drug Metab Toxicol 2013,9(8),1053-1059","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/171447","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T14:58:27Z","timestamp":1694789907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/171447\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,5,27]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557519666190408154443","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,27]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-11-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}